ERCP-Related Adverse Events in Primary Sclerosing Cholangitis: A Systematic Review and Meta-Analysis

Table 7

Summary of results.

30-day ERCP-related adverse events in patients with and without PSC
Population: adults with PSC; Setting: inpatient and outpatient; Intervention: ERCP; Comparison: adults without PSC
Outcome	Relative effect (95% CI)	Number of patients (studies)	Sensitivity analysis (95% CI)	Number of patients (studies)	Certainty of the evidence (GRADE)
Cholangitis	OR 3.263 (1.076–9.896), , I^2 = 73.0%	715 with PSC and 9979 without PSC (4)	OR 5.159 (2.080–12.796), , I^2 = 39.9%	339 with PSC and 9817 without PSC (3)	Very low
Pancreatitis	OR 0.888 (CI 0.257–3.069), , I^2 = 87.9%		OR 1.794 (1.002–3.214), , I^2 = 29.3%		Very low
Bleeding	OR 0.363 (0.060–2.214), , I^2 = 50.3%		OR 0.782 (0.207–2.959), , I^2 = 3.8%		Very low
Perforation	OR 1.191 (0.402–3.515), , I^2 = 28.5%		OR 1.666 (0.686–4.046), , I^2 = 0.0%		Very low
Risk factors for 30-day post-ERCP pancreatitis
Population: adults with PSC; Setting: inpatient and outpatient; Intervention: ERCP; Comparison: N/A
Risk factor	Relative effect (95% CI)	Number of procedures (studies)	Certainty of the evidence (GRADE)
Female sex	OR 1.546 (0.882–2.709), , I^2 = 47.6%	3824 (5)	Very low
Accidental passage of wire into the pancreatic duct	OR 7.444 (3.328–16.651), , I^2 = 65.0%	3098 (3)	Very low
Biliary sphincterotomy	OR 4.802 (1.916–12.033), , I^2 = 73.1%	3824 (5)	Very low

CI, confidence interval; ERCP, endoscopic retrograde cholangiopancreatography; GRADE, Grading of Recommendations, Assessment, Development, and Evaluations; N/A, not applicable; OR, odds ratio; PSC, primary sclerosing cholangitis.